Skip to search formSkip to main contentSkip to account menu

E7080

Known as: Multi-Kinase Inhibitor E7080 
A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with… 
National Institutes of Health

Related topics

Related topics

2 relations
lenvatinib

Broader (1)

lenvatinib mesylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Phase I/II study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results.
231 Background: Lenvatinib is an oral tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-4, RET, KIT and PDGFR-beta. Maximum… 
2013
2013
A phase Ib clinical trial of the multitargeted kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).
358 Background: Lenvatinib (L) is an oral tyrosine kinase inhibitor targeting VEGFR1-3, FGFR 1-4, RET, KIT, and PDGFβ. Everolimus… 
2012
2012
A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).
5591 Background: Lenvatinib is an oral tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-4, RET, KIT and PDGFRβ. In phase I… 
2012
2012
Phase I/II study of E7080 (lenvatinib), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Initial assessment of response rate.
320 Background: Lenvatinib is an oral tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-4, RET, KIT and PDGFRβ. Maximum… 
2012
2012
Model-based treatment optimization of a novel VEGFR inhibitor.
AIM To evaluate dosing and intervention strategies for the phase II programme of a VEGF receptor inhibitor using PK-PD modelling… 
2010
2010
Abstract 3614: Multi-targeted kinase inhibitor E7080 showed anti-tumor activity against medullary thyroid carcinoma and squamous thyroid carcinoma cell line based on RET and VEGFR2 tyrosine kinase…
There are about 37,000 and 8,000 new cases of thyroid cancer each year in the US and JP respectively, according to reports of the… 
2008
2008
Phase I dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors
14583 Background: E7080, a multikinase inhibitor, has potent inhibitory activity against the split-kinase family of transmembrane… 
2008
2008
Phase I dose escalation study and biomarker analysis of E7080 in patients with advanced solid tumors
3527 Background: E7080 is an oral multi-targeted kinase inhibitor of VEGFRs, PDGFRs, FGFRs and c-kit. Methods: This study was… 
2007
2007
A phase I dose finding study of E7080 in patients (pts) with advanced malignancies
14073 Background: E7080 is a potent inhibitor of the split-kinase family of transmembrane growth factor receptors including Flt-1… 
2006
2006
E7080, an oral multitargeted tyrosine kinase inhibitor, has direct anti-tumor efficacy via inhibition of KIT signaling in gastrointestinal stromal tumor (GIST)
Proc Amer Assoc Cancer Res, Volume 47, 2006 4038 Most gastrointestinal stromal tumors (GIST) express constitutively active… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)